Sebelipase alfa for lysosomal acid lipase deficiency: 5‐year treatment experience from a phase 2 open‐label extension study

समान संसाधन

• Novel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfa
  द्वारा: Su, Kim, और अन्य
  प्रकाशित: (2016)
• Sebelipase alfa over 52 weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency
  द्वारा: Valayannopoulos, Vassili, और अन्य
  प्रकाशित: (2014)
• The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency
  द्वारा: Erwin, Angelika L.
  प्रकाशित: (2017)
• Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
  द्वारा: Jones, Simon A., और अन्य
  प्रकाशित: (2017)
• Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies
  द्वारा: Vijay, Suresh, और अन्य
  प्रकाशित: (2021)